托伐普坦用于治疗多囊肝肿大疾病。
Tolvaptan for the Treatment of Enlarged Polycystic Liver Disease.
作者信息
Mizuno Hiroki, Hoshino Junichi, Suwabe Tatsuya, Sumida Keiichi, Sekine Akinari, Oshima Yoichi, Oguro Masahiko, Kunizawa Kyohei, Kawada Masahiro, Hiramatsu Rikako, Hayami Noriko, Hasegawa Eiko, Yamanouchi Masayuki, Sawa Naoki, Takaichi Kenmei, Ubara Yoshifumi
机构信息
Nephrology Center, Toranomon Hospital Kajigaya, Kawasaki, Japan.
Okinaka Memorial Institute for Medical Research, Toranomon Hospital Kajigaya, Kawasaki, Japan.
出版信息
Case Rep Nephrol Dial. 2017 Jul 19;7(3):108-111. doi: 10.1159/000477664. eCollection 2017 May-Aug.
A 44-year-old Japanese woman with autosomal dominant polycystic kidney disease was admitted to our hospital for evaluation of abdominal distension. Her eGFR was 53.7 mL/min/1.73 m. Total kidney volume was 2,614 mL. Tolvaptan (60 mg/day) was started to treat renal involvement. The patient's abdominal fullness began to improve and liver volume, indicating advanced polycystic liver disease (PLD), decreased from 9,750 mL to 8,345 mL after 17 months of tolvaptan treatment, though there was no significant change in kidney volume. This case indicates that tolvaptan may be a therapeutic option for hepatomegaly in patients with symptomatic PLD.
一名44岁的患有常染色体显性遗传性多囊肾病的日本女性因腹胀入院接受评估。她的估算肾小球滤过率（eGFR）为53.7 mL/（min·1.73 m²）。双肾总体积为2614 mL。开始使用托伐普坦（60毫克/天）治疗肾脏病变。患者的腹部胀满开始改善，且在接受托伐普坦治疗17个月后，提示晚期多囊肝病（PLD）的肝脏体积从9750 mL降至8345 mL，尽管肾脏体积无显著变化。该病例表明，托伐普坦可能是有症状的PLD患者肝肿大的一种治疗选择。
Zotero 插件